ABL Bio Inc
KOSDAQ:298380
Intrinsic Value
ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. [ Read More ]
The intrinsic value of one ABL Bio Inc stock under the Base Case scenario is 8 374.41 KRW. Compared to the current market price of 25 400 KRW, ABL Bio Inc is Overvalued by 67%.
Valuation Backtest
ABL Bio Inc
Run backtest to discover the historical profit from buying and selling ABL Bio Inc stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
ABL Bio Inc
Current Assets | 102.6B |
Cash & Short-Term Investments | 100.6B |
Receivables | 331.5m |
Other Current Assets | 1.6B |
Non-Current Assets | 100.3B |
Long-Term Investments | 89.8B |
PP&E | 6.4B |
Intangibles | 2.6B |
Other Non-Current Assets | 1.5B |
Current Liabilities | 103.7B |
Accrued Liabilities | 344.8m |
Short-Term Debt | 40B |
Other Current Liabilities | 63.4B |
Non-Current Liabilities | 3.3B |
Long-Term Debt | 409.9m |
Other Non-Current Liabilities | 2.9B |
Earnings Waterfall
ABL Bio Inc
Revenue
|
104.8B
KRW
|
Operating Expenses
|
-70.1B
KRW
|
Operating Income
|
34.7B
KRW
|
Other Expenses
|
1.4B
KRW
|
Net Income
|
36.1B
KRW
|
Free Cash Flow Analysis
ABL Bio Inc
Profitability Score
Profitability Due Diligence
ABL Bio Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Score
ABL Bio Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
ABL Bio Inc's solvency score is 77/100. The higher the solvency score, the more solvent the company is.
Score
ABL Bio Inc's solvency score is 77/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
ABL Bio Inc
According to Wall Street analysts, the average 1-year price target for ABL Bio Inc is 36 720 KRW with a low forecast of 35 350 KRW and a high forecast of 38 850 KRW.
Shareholder Return
Price
ABL Bio Inc
Average Annual Return | 1.12% |
Standard Deviation of Annual Returns | 29.93% |
Max Drawdown | -58% |
Market Capitalization | 1.2T KRW |
Shares Outstanding | 47 892 500 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
Contact
IPO
Employees
Officers
The intrinsic value of one ABL Bio Inc stock under the Base Case scenario is 8 374.41 KRW.
Compared to the current market price of 25 400 KRW, ABL Bio Inc is Overvalued by 67%.